Rejuvenate Biomed closes in on €9 million funding round for human trials of sarcopenia-targeted combined drug.
Already well-known for its beer and bureaucracy to its...
Insilico announces Pandomics, an AI-powered hypothesis generation engine that interprets OMICS and text-based data for the discovery and analysis of new therapeutic targets.
Insilico is...
Scientists studying how the microbiome affects our mood aim to develop gut microbiome-modulating formulations to treat depression and other brain diseases.
Recent work from Katya...
Phase 2-ready drug can treat and reverse immune aging, BioAge claims.
BioAge Labs' in-licensed clinical-stage therapy has potential for treating immune aging in older patients...
Leading academic says high profile trial failures should drive changes in how we approach trials for drugs that target aging.
Following the recent clinical trial...
Buck professor Brian Kennedy talks about AKG and the potential for supplements to deliver real anti-aging benefits.
Following Tuesday’s news from the Buck Institute about...
The Buck's new peer-reviewed study of alpha-ketoglutarate shows a significant reduction in frailty in older mice, resulting in compression of late-life morbidity.
The Buck Institute...
Relation receives $1.3m grant funding from the Gates Foundation to identify COVID-19 therapeutic candidates.
Relation Therapeutics (a Juvenescence-incubated company) and Mila, the Montreal-based AI research...
As Healthy Aging Month arrives, Dr Thomas Rando shares his views on progress in Longevity science.
For the past two decades, September has been celebrated...
We speak to the co-founder of Molecule about building a unique marketplace for early stage therapeutic development.
Next week (September 1 - 4), the annual...
Senolytic research in humans may be in its infancy, but there is reason for cautious optimism.
Last week we reported on biotech company UNITY's decision...
Encouraging news from Elysium Health illustrates that the Longevity supplements market is building clinical and commercial traction.
In December 2019, Elysium announced a $40m Series...
Nuchido’s systems pharmacology approach yields NAD+ supplement that claims to boost levels by 242%!
A new player in the NAD+ supplement market has arrived...
Company to focus on ophthalmologic and neurologic programs as Phase 2 knee osteoarthritis clinical study fails to meet primary endpoint.
Senolytic therapy developer UNITY...
Juvenescence's Greg Bailey on democratising healthcare, paradigm shifts and disruptive technologies.
Yesterday we published the first part of our interview with Greg Bailey, CEO of...
A new blood test could diagnose Alzheimer’s Disease 20 years before symptoms appear, paving the way for breakthroughs in research and treatment.
It's hoped the...
Recent study identifies critical regulator of protein biosynthesis recovery and homeostasis required for Longevity.
Unresolved DNA damage caused by intrinsic and environmental factors accumulates during...
Start the clock to stop the clock – centralised data will aid Longevity research.
Deep Longevity, which engages in the development of explainable AI systems...
Tracked.bio develops AI computer vision system that tracks flies and mice to reduce man-hours and increase data collected in Longevity studies.
A Danish start-up aims...
Following an R&D collaboration that began last year, Japanese pharma Astellas has announced it will acquire bioelectronics firm iota in $304m deal.
Last year's R&D...
![Ozone therapy recently hit the headlines as one of the many treatment options being examined to mitigate the effects of COVID-19 [1], but it is also showing great promise in the treatment of neurodegenerative conditions such as Alzheimer’s and Parkinson's.](https://www.longevity.technology/wp-content/uploads/2020/10/Ozone-therapyW-218x150.jpg "Stopping neurodegeneration in its tracks with ozone therapy")
